Perhaps there remains sufficient heterogeneity, with regard to CTLA-4 expression, such that lymphoproliferation can occur with CTLA4− malignant B-cells in the lymph node with concurrent inhibition of anti-tumor responses by CTLA-4+ malignant B-cells in peripheral blood or bone marrow, thus favoring overall tumor progression. Here, CTLA4 is linked to neoplasm.